Baby swabs and nasal swabs recalled for possible fungus in swab parts
Swabs for teething babies and adult noses have been recalled because they might have a microbial contamination 'identified as fungi in cotton swab components.'
That's what manufacturer Church & Dwight said in its notice announcing the recall of Orajel Baby Teething Swabs, Zicam Cold Remedy Nasal Swabs and Zicam Nasal AllClear Swabs from stores across the United States, including Puerto Rico.
The lots and expiration dates involved? All.
READ MORE: Recalled UTI drug could have deadly microbial contamination
Swabs with a microbial contamination can cause 'serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injurie,' the recall notice states. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.'
▪ Zicam Cold Remedy Nasal Swabs carry UPC No. 732216301205.
▪ Zicam Nasal AllClear Swabs, which were discontinued in December, carry UPC No. 732216301656.
▪ Orajel baby swabs carry UPC No. 310310400002.
If you have the swabs, throw them in the trash or, for a refund, reach out go Church & Dwight either online or by calling 800-981-4710. Questions can be directed to that phone number, 9 a.m. to 5 p.m., Monday through Friday.
If you think you or your baby is having a medical issue caused by these swabs, go see a medical professional. Then, notify the FDA's MedWatch Adverse Event Program, either by filling out a form online or by requesting a reporting form at 800-332-1088.
Then, third, call Church & Dwight.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy
LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe, who progress rapidly to end-stage heart failure. NVC-001 demonstrated significant benefits, including survival and cardiac function in preclinical models. IND clearance enables initiation of first-in-human, ascending-dose Phase 1/2 clinical trial in early 2026. SINGAPORE and PHILADELPHIA, June 10, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NVC-001. NVC-001 is an adeno-associated virus (AAV)-based gene therapy designed to treat LMNA-related dilated cardiomyopathy (LMNA DCM). Nuevocor plans to initiate an open-label, ascending-dose Phase 1/2 clinical trial of NVC-001 in patients with LMNA DCM. "This IND clearance marks a significant milestone in our mission to develop transformative therapies for patients with genetic cardiomyopathies by leveraging unique insights from our proprietary PrOSIA mechanobiology platform," said Dr. Yann Chong Tan, co-founder and CEO of Nuevocor. "NVC-001 is the first disease-modifying therapy for LMNA DCM designed to address the underlying mechanobiological root cause of disease. We look forward to initiating our clinical trial to bring this potentially life-changing therapy to patients." LMNA DCM is a serious genetic heart condition caused by mutations in the LMNA gene, which encodes lamin A/C – a protein essential for maintaining nuclear envelope integrity and regulating gene expression in cardiac cells. Mutations in LMNA lead to a weakening of the heart muscle, arrhythmias, and progression to end-stage heart failure. LMNA DCM is estimated to affect approximately 100,000 patients in the U.S. and Europe, representing a significant unmet medical need. NVC-001 is engineered to address the functional mechanical root cause of disease by reducing aberrant mechanical stress on the nucleus, thereby restoring nuclear envelope integrity. Nuclear envelope disruption is a hallmark of LMNA DCM. In preclinical studies, treatment with NVC-001 demonstrated significant benefits, including survival and cardiac function. The planned Phase 1/2 clinical trial is a first-in-human, 52-week open-label, multicenter, ascending-dose study designed to evaluate the safety, tolerability, and preliminary efficacy of NVC-001 in adult subjects with LMNA-DCM. NVC-001 will be administered as a one-time intravenous infusion to patients in ascending-dose cohorts. About Nuevocor Nuevocor is biotechnology company developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology, headquartered in Singapore with an office in the U.S. and expansion to Europe. Our unique approach, enabled by our proprietary PrOSIA mechanobiology platform, surpasses the limitations of traditional gene replacement therapy – which treats individual gene mutations – to treating defects in shared disease pathways across multiple cardiomyopathies by addressing the functional root cause of disease. Nuevocor is first-in-disease by addressing genetic cardiomyopathies that are not amendable to gene replacement therapy and have no effective treatment options. ( View original content to download multimedia: SOURCE Nuevocor Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
CN Bio introduces cross-species DILI services to enhance
CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal microphysiological system (MPS) models that enhance translatability in preclinical drug safety and toxicology assessments to its Contract Research Services (CRS). Building upon the Company's FDA-recognized drug induced liver injury (DILI) assay, the expanded offering enables rapid, comparative studies between commonly used animal and human models to flag interspecies differences early, and better informs in vivo study design. Traditional human in vitro methods have limited capacity to accurately determine drug toxicity. Added to this, the discrepancies between these methods and in vivo animal studies make it challenging to accurately predict safety risks for humans during preclinical testing. Often, unsafe drug candidates are wrongly progressed, and potentially life-saving ones are misclassified and abandoned, ultimately impacting clinical progression. In response to growing market demand for tools that address these concerns, CN Bio has expanded the in vitro to in vivo extrapolation (IVIVE) capabilities of its established PhysioMimix ® DILI assay, adding the ability to easily compare results across human-, rat-, and dog-derived Liver-on-a-chip models. These assays offer a modernized workflow to generate predictive and actionable insights that mitigate the risk of costly, late-stage conflicting data, and reduce unnecessary animal use by providing early warning of hepatotoxicity/DILI prior to in vivo studies. Accessible through the Company's CRS, the new offering harnesses the longstanding expertise of CN Bio's scientific team to provide detailed data analysis, optimized outcomes, and data-driven conclusions beyond what is achievable using existing in vitro models. The assay enables a broad range of longitudinal and endpoint testing for DILI-specific biomarkers from single- or repeat-dosing studies over a 14-day experimental window. This provides a more comprehensive overview of underlying mechanisms of hepatotoxicity or latent effects of drug candidates to improve IVIVE assessment and streamline clinical progression. Dr Emily Richardson, Lead Scientist, Safety and Toxicology, CN Bio, said: 'Understanding safety risks is critical to successful drug development, however, fundamental physiological and biological differences between species can lead to inaccuracies in predictions, often causing drug candidates to be wrongfully abandoned as toxic, or worse, mistakenly classified as safe.' She added: 'Having established our DILI assay as an industry leading option to garner more valuable insights across the development pipeline, we were in an ideal position to expand its capabilities and address this crucial gap in understanding hepatotoxicity using the most commonly used animal models. Partnering with us to utilize this powerful service not only ensures robust and reliable results but also provides access to a team of Organ-on-a-chip experts, who are invested in your success; to de-risk your pipeline and move it forward with confidence.'
Business Wire
3 hours ago
- Business Wire
Emulate Launches AVA™ Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented magnitude of in vivo -level insights faster than animal models while cutting consumable costs four-fold and in-lab labor by half compared to current generation technologies. These transformative capabilities give the pharmaceutical industry the practical means to pivot beyond animal testing and into truly human-relevant territory. With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program. Share 'AVA gives scientists unprecedented experimental capacity with the biological depth of live human tissue—something no other platform can match,' said Jim Corbett, Chief Executive Officer at Emulate. 'By combining Emulate's proven Organ-on-a-Chip technology with high-throughput consumables, automated imaging, and streamlined workflows in one benchtop unit, AVA lets teams ask bigger questions earlier and move the right drug candidates forward faster.' AVA Emulation System: Three Instruments in One AVA is the first self-contained Organ-on-a-Chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit. Key performance gains include: Expanded experimental power – 96 independent Organ-Chip samples in a single run enable researchers to achieve microplate-level scale of their Organ-Chip experiments, enabling side-by-side comparison of dozens of compounds, doses, or stimuli. Lower operating costs – AVA achieves a four-fold drop in consumable spend and up to 50% fewer cells and media per sample compared to previous generation technology. Time & labor savings – Hands-on, in-lab time is reduced by more than half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array™ consumable that integrates 12 independent Organ-Chips into an SBS format for streamlined workflows with multichannel pipettes and automated liquid handlers. AI-ready datasets – A typical 7-day experiment can generate >30,000 time-stamped data points from daily imaging and effluent assays, with post-takedown omics pushing the total into the millions—providing a rich, multi-modal foundation to feed machine-learning pipelines for target discovery, lead optimization, and safety prediction. A Timely Answer to Shifting Regulations With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program—has already outperformed animals, showing 87% sensitivity and 100% specificity for drug-induced liver injury in a 2022 Communications Medicine study. AVA now scales that level of human relevance across discovery, efficacy, and toxicology screens, accelerating safer therapies through the pipeline. 'Moving towards reduction and in some cases replacement of animal models demands both biological fidelity and throughput,' noted Dr. Lorna Ewart, Emulate Chief Scientific Officer. 'AVA meets those dual requirements, empowering teams to rank-order lead candidates, pinpoint off-target toxicities, and advance safer therapies with unprecedented speed and confidence.' Broad Impact Across Industries In biopharma, this type of reduction and replacement is already a reality. A leading pharmaceutical company has demonstrated the power of implementing Organ-Chips into their development pipeline when one of their scientists saved millions of dollars and years of development time by using Emulate Liver-Chips ahead of non-human primates to screen lipid-nanoparticle (LNP) candidates. AVA's leap in throughput of predictive human biology stands to benefit not only biopharma but a wide spectrum of sectors that currently rely on inaccurate animal testing. Large pharmaceutical pipelines can now run comparable screens in a single AVA experiment, while smaller biotech teams gain enterprise-level capacity without adding headcount or infrastructure. Beyond therapeutics, contract research organizations, consumer-product companies, and environmental agencies can harness AVA to evaluate industrial chemicals, food additives, and cosmetic ingredients under human-relevant conditions—bringing faster, more ethical safety and efficacy decisions to market-driven and regulatory programs alike. Availability Global orders are open immediately. For pricing or demonstrations, please submit a request here. About Emulate Emulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation in vitro models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research—one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate's Organ-Chip platforms, consumables, and organ models help the world's leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies. Learn more at
